These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22863114)

  • 1. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial.
    Murakami K; Habukawa C; Nobuta Y; Moriguchi N; Takemura T
    Biopsychosoc Med; 2012 Aug; 6(1):16. PubMed ID: 22863114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combined consumption of Lactobacillus brevis KB290 and β-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Fuke N; Aizawa K; Suganuma H; Takagi T; Naito Y
    Int J Food Sci Nutr; 2017 Dec; 68(8):973-986. PubMed ID: 28391736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS; Sohn W; Lee OY; Lee SP; Lee KN; Jun DW; Lee HL; Yoon BC; Choi HS; Chung WS; Seo JG
    J Gastroenterol Hepatol; 2014 Jan; 29(1):52-9. PubMed ID: 23829297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.
    Cui S; Hu Y
    Int J Clin Exp Med; 2012; 5(3):238-44. PubMed ID: 22837798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V; Gschossmann J; Layer P
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):658-666. PubMed ID: 32277872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of New
    Oh JH; Jang YS; Kang D; Chang DK; Min YW
    Nutrients; 2019 Nov; 11(12):. PubMed ID: 31783597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives.
    Maixent JM; Pons O; Sennoune SR; Sadrin S
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):211-214. PubMed ID: 32538776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial.
    Bogovič Matijašić B; Obermajer T; Lipoglavšek L; Sernel T; Locatelli I; Kos M; Šmid A; Rogelj I
    J Dairy Sci; 2016 Jul; 99(7):5008-5021. PubMed ID: 27157575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
    Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L
    World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome.
    Stevenson C; Blaauw R; Fredericks E; Visser J; Roux S
    Nutrition; 2014 Oct; 30(10):1151-7. PubMed ID: 25194614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of probiotic Lactobacillus brevis KB290 on incidence of influenza infection among schoolchildren: an open-label pilot study.
    Waki N; Matsumoto M; Fukui Y; Suganuma H
    Lett Appl Microbiol; 2014 Dec; 59(6):565-71. PubMed ID: 25294223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Giannetti E; Maglione M; Alessandrella A; Strisciuglio C; De Giovanni D; Campanozzi A; Miele E; Staiano A
    J Clin Gastroenterol; 2017 Jan; 51(1):e5-e10. PubMed ID: 27306945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial.
    Ligaarden SC; Axelsson L; Naterstad K; Lydersen S; Farup PG
    BMC Gastroenterol; 2010 Feb; 10():16. PubMed ID: 20144246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial.
    Sadrin S; Sennoune SR; Gout B; Marque S; Moreau J; Grillasca J; Pons O; Maixent JM
    Cell Mol Biol (Noisy-le-grand); 2017 Sep; 63(9):122-131. PubMed ID: 28980935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.